Moreover, NSCLC cells with different mRNA levels of EMT-TFs and Vimentin, differ in drug response to MTA, with the cells that express higher EMT-TFs and Vimentin, display higher chemoresistance (Figures 2f and g, 4b and c and Supplementary Table S1). This evidence concerns the gene VIM and non-small cell lung carcinoma.